Compound News and Research

RSS

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

Combination therapy benefits patients with acute myeloid leukemia

Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.

8 Dec 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

8 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

An international research collaborative has determined that a promising anti-malarial compound tricks the immune system to rapidly destroy red blood cells infected with the malaria parasite but leave healthy cells unharmed. St. Jude Children's Research Hospital scientists led the study, which appears in the current online early edition of the Proceedings of the National Academy of Sciences.

5 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

New drug offers hope for victims of spinal cord injury

Scientist in the U.S have developed a drug that could help paralysed victims of spinal cord injury regain their ability to move.

4 Dec 2014

New chemical compound shows promise in restoring function lost to spinal cord injury

Case Western Reserve scientists have developed a new chemical compound that shows extraordinary promise in restoring function lost to spinal cord injury. The compound, which the researchers dubbed intracellular sigma peptide (ISP), allowed paralyzed muscles to activate in more than 80 percent of the animals tested.

4 Dec 2014

Scientists report new approach to defeating asthma by targeting allergen

Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don't get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating asthma by targeting the trigger -- the allergen -- before it can spark an attack. They describe their new compound, which they tested on rats, in ACS' Journal of Medicinal Chemistry.

3 Dec 2014

Researchers find way to prevent noise-induced hearing loss

Researchers from Weill Cornell Medical College and the Gladstone Institutes have found a way to prevent noise-induced hearing loss in a mouse using a simple chemical compound that is a precursor to vitamin B3. This discovery has important implications not only for preventing hearing loss, but also potentially for treating some aging-related conditions that are linked to the same protein.

3 Dec 2014

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

BioPharmX Corporation, a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration for the company's topical antibiotic acne compound currently under development.

2 Dec 2014

Faster and more accurate method for testing new cancer drugs

Finding faster and more accurate ways to test new cancer drugs is always a priority for cancer researchers.

2 Dec 2014

Global stem cell market estimated to reach US$117.66B in 2018

Stem cells have the potential to transform healthcare by enabling the cost-effective treatment of many conditions that currently have poor treatment options.

2 Dec 2014

Researchers develop low-cost, electricity-free device for detecting DNA of infectious pathogens

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers funded by the National Institutes of Health have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

2 Dec 2014

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.

2 Dec 2014

Sanford-Burnham, Mayo Clinic scientists to jointly find new treatment for resistant hypertension

Sanford-Burnham Medical Research Institute at Lake Nona and Mayo Clinic today announced that a joint team of scientists has been selected as a winner of GlaxoSmithKline's 2014 Discovery Fast Track Challenge.

2 Dec 2014

Predictive model provides information for treating 20% of human diseases

The analysis of drugs, natural products, and chemical substances found in the environment allows the identification of the chemical fragments responsible for a therapeutic or deleterious effect on human health.

1 Dec 2014

European scientists develop, test drug that could reduce harmful side-effects of 'binge drinking'

A drug that could reduce the harmful side-effects of 'binge drinking', especially by teenagers, has been successfully developed and tested by a team of European scientists, including the University of Huddersfield's Professor Mike Page and Dr Karl Hemming. There is also the potential for new ways to treat Alzheimer's and other neurological diseases that damage the brain.

27 Nov 2014

Compound News and Research

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Combination therapy benefits patients with acute myeloid leukemia

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Novel targeted therapies and treatment combinations for leukemia

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

New drug offers hope for victims of spinal cord injury

New chemical compound shows promise in restoring function lost to spinal cord injury

Scientists report new approach to defeating asthma by targeting allergen

Researchers find way to prevent noise-induced hearing loss

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

Faster and more accurate method for testing new cancer drugs

Global stem cell market estimated to reach US$117.66B in 2018

Researchers develop low-cost, electricity-free device for detecting DNA of infectious pathogens

Ligand indazole chloride improves motor function, study shows

Sanford-Burnham, Mayo Clinic scientists to jointly find new treatment for resistant hypertension

Predictive model provides information for treating 20% of human diseases

European scientists develop, test drug that could reduce harmful side-effects of 'binge drinking'

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News